Detection of 5α-reductase inhibitors by UPLC-MS/MS: Application to the definition of the excretion profile of dutasteride in urine.
UPLC-MS/(MS)
anti-doping analysis
athlete biological passport
confounding factors
dutasteride
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
02
08
2019
revised:
22
09
2019
accepted:
23
09
2019
pubmed:
21
11
2019
medline:
19
5
2020
entrez:
21
11
2019
Statut:
ppublish
Résumé
An analytical procedure based on ultra-performance liquid chromatography-mass spectrometry was developed to screen and to confirm dutasteride and its metabolites in human urine. Sample preparation included an enzymatic hydrolysis followed by solid-phase extraction using the strong cation exchange cartridges OASIS
Substances chimiques
5-alpha Reductase Inhibitors
0
Dutasteride
O0J6XJN02I
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1737-1746Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Azzouni F, Godoy A, Li Y, Mohler J. The 5alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Advances in Urology. 2012;2012:1-18.
Yamana K, Fernand L, Luu-The V. Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig. 2010;2(3):293-299.
Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview on 5α-reductase inhibitors. Steroids. 2010;75(2):109-153.
Chen W, Zouboulis CC, Orfanos CE. The 5α-reductase system and its inhibitors. Recent Development and its Perspective in Treating Androgen-Dependent Skin Disorders, Dermatology. 1993;193:177-184.
Hoffmann R. Steroidogenic isoenzymes in human hair and their potential role in androgenetic alopecia. Dermatology. 2003;206(2):85-95.
Kelly Y, Blanco A, Tosti A. Androgenetic alopecia: an update of treatment options. Drugs. 2016;76(14):1349-1364.
Gubelin Harcha W, Barboza Martinez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J am Acad Dermatol. 2014;70(3):489-498.e3.
Cardarelli-Leite L, de Assis AM, Moreira AM, et al. Impact of 5-alpha-reductase inhibitors use at the time of prostatic artery embolization for treatment of benign prostatic obstruction. J Vasc Interv Radiol. 2019;30(2):228-232.
Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5α-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29(1):17-25.
Tarter TH, Vaughan ED. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia. Curr Pharm des. 2006;12:775-783.
Clark RV, Hermann DJ, Cunnungham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179-2184.
Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434-441.
Cilotti A, Danza G, Serio M. Clinical application of 5alpha-reductase inhibitors. J Endocrinol Invest. 2001;24(3):199-203.
Foley CL, Kirby RS. 5 alpha-reductase inhibitors: What's new? Curr Opin Urol. 2003;13(1):31-37.
Aggawal S, Thareja S, Bhardwaj TR, Kumar M. Ligand based 3D-QSAR study on a series of steroidal human 5αreductase inhibitors. Letters in Drug Design and Discovery. 2010;7(8):596-601.
Vermeulen A, Giagulli VA, De Schepper P, Buntinx A, Stoner E. Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans. Prostate. 1989;14(1):45-53.
Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6:S31-S39.
Fossler M, Zhu J, Roehrborn C, McAleese P, Manyak M. Impact of formulation on the pharmacokinetics of dutasteride: results from two phase I studies. Clin Drug Investig. 2016;36(9):763-767.
Keam SJ, Scott LJ. Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463-485.
Geyer H, Nolteernsting E, Schänzer W. Finasteride: a substance for manipulation in dope control? In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping analysis (7). Cologne, Germany: Sport & Buch Strauss; 1999:71-80.
Mareck U, Geyer H, Opfermann G, Thevis M, Schänzer W. Factors influencing the steroid profile in doping control analysis. J Mass Spectrom. 2008;43:419-435.
Simoes S, Vitoriano B, Manzoni C, de la Torre X. 5-Alpha Reductase Inhibitors Detection in Doping Analysis. In: Schänzer W, Geyer H, Gotzmann A, Mareck U, eds. Recent Advances in Doping analysis (13). Cologne, Germany: Sport & Buch Strauss; 2005:199-209.
Thevis M, Geyer H, Mareck U, Flenker U, Schänzer W. Doping-control analysis of the 5α-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite. Ther Drug Monit. 2007;29(2):236-247.
World Anti-Doping Agency. The 2005 Prohibited List. International Standard, Montreal (2005) Available at: www.wada-ama.org. (last accessed: March 5th 2019).
World Anti-Doping Agency. The 2009 Prohibited List. International Standard, Montreal (2009) Available at: www.wada-ama.org. (last accessed: March 5th 2019).
World Anti-doping Agency (WADA), WADA Technical Document - TD2014AAS https://www.wada-ama.org, 2014. (last accessed: March 5th 2019).
Macek J. Separation of finasteride and analogues. J Chromatogr B. 2001;764(1-2):207-215.
Carlin JR, Hӧglund P, Eriksson LO, et al. Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. 2014;339-351.
Thorngren J-O, Ostervall F, Garle MA. High-throughput multicomponent screening method for diuretics, masking agents, central nervous system (CNS) stimulants and opiates in human urine by UPLC-MS/MS. J Mass Spectrom. 2008;43:419-435.
Mazzarino M, de la Torre X, Botrè F. A screening method for the simultaneous detection of glucocorticoids, diuretics, stimulants, anti-oestrogens, beta-adrenergic drugs and anabolic steroids in human urine by LC-ESI-MS/MS. Anal Bioanal Chem. 2008;392(4):681-698.
Ventura R, Roig M, Montfort N, Saez P, Berges R, Segura J. High-throughput and sensitive screening by ultra-performance liquid chromatography tandem mass spectrometry of diuretics and other doping agents. Eur J Mass Spectrom. 2008;14(3):191-200.
Brun EM, Torres A, Ventura R, Puchades R, Maquieira Á. Enzyme-linked immunosorbent assays for doping control of 5α-reductase inhibitors finasteride and dutasteride. Anal Chim Acta. 2010;671(1-2):70-79.
Agarwal S, Gowda KV, Sarkar AK, et al. Simultaneous determination of tamsulosin and dutasteride in human plasma by LC-MS-MS. Chromatographia. 2008;67(11-12):893-903.
Gomes NA, Pudage AM, Joshi SS, Vaidya VV, Parekh SA, tamhankar AV. Rapid and sensitive LC-MS-MS method for the simultaneous estimation of Alfuzosin and Dutasteride in human plasma. Chromatographia. 2008;69:9-18.
Ramakrishna NVS, Kandikere V, Singhal P, Koteshwara M, Manoj S, Maurya S. Selective and rapid liquid chromatography-tandem mass spectrometry assay of dutasteride in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2004;809(1):117-124.
Kamat SS, Choudhari VB, Vele VT, Prabhune SS. Determination of dutasteride by LC: validation and application of the method. Chromatographia. 2008;67(11-12):911-916.
Contractor P, Kurani H, Guttikar S, Shrivastav PS. Reliable and sensitive determination of dutasteride in human plasma by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2013;27(9):1168-1176.
Mazzarino M, Calvaresi V, de la Torre X, Parrotta G, Sebastianelli C, Botrè F. Development and validation of a liquid chromatography-mass spectrometry procedure after solid phase extraction for detection of 19 doping peptides in human urine. Forensic Toxicol. 2015;33(2):321-337.
Mazzarino M, Cesarei L, de la Torre X, Fiacco I, Robach P, Botrè F. A multi-targeted liquid chromatography-mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes. J Pharm Biomed Anal. 2016;117:47-60.
Mazzarino M, Abate MG, Alocci R, et al. Urine stability and steroid profile: towards a screening index of urine sample degradation for anti-doping purpose. Anal Chim Acta. 2011;683(2):221-226.
Palermo A, Botrè F, de la Torre X, Fiacco I, Iannone M, Mazzarino M. Drug-drug interactions and masking effects in sport doping: influence of miconazole administration on the urinary concentrations of endogenous anabolic steroids. Forensic Toxicology. 2016;34(2):386-397.
International Organization for Standardization, ISO/IEC17025:2017, Available at www.iso.org (last accessed 30th May 2019).
World Anti-Doping Agency, International Standard for Laboratories, 2019, Available at www-wada.org (last accessed 30th May 2019).
World Anti-Doping Agency, Technical Documents, (WADA Technical Document TD 2019MRPL) available at www-wada.org (last accessed 30th May 2019).
World Anti-Doping Agency. Identification criteria for qualitative assays incorporating column chromatography and mass spectrometry, (WADA Technical Document TD 2015IDCR) Available: http://www.wada-ama.org (last accessed 30th May 2019).
Burinsky DJ, Williams JD, Thornquest AD, Sides SL. Mass spectral fragmentation reactions of a therapeutic 4-azasteroid and related compound. J Am Soc Mass Spectrom. 2001;12(4):385-398.
World Anti-Doping Agency. Harmonization of analysis and reporting of 19-norsteroids related to nandrolone, (WADA Technical Document TD2019NA). Available: https://www.wada-ama.org (last accessed 30th May 2019).